Online inquiry

IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3034MR)

This product GTTS-WQ3034MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ITGA4&ITGB7&ITGAE gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000885.6; NM_000889.3; NM_002208.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3676; 3695; 3682
UniProt ID P13612; P26010; P38570
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ3034MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8871MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ4000MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BGB-A317
GTTS-WQ9037MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ11782MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-3222
GTTS-WQ6656MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ8053MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA h2H12ec
GTTS-WQ12273MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MRA
GTTS-WQ6401MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CT-011
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW